Table 3.
Characteristics of HBsAg-positive patients with hepatic dysfunction and without hepatic dysfunction during chemotherapy
| Patients with hepatic dysfunction (No = 40) (49.4%) | Patients without hepatic dysfunction (No = 41) (50.6%) | p-value | |
| Sex | 0.22 | ||
| Male | 23(57.5) | 18(43.9) | |
| Female | 17(42.5) | 23(56.1) | |
| Age (years) | 0.096 | ||
| ≤ 60 | 28(70) | 35(85.4) | |
| > 60 | 12(30) | 6(14.6) | |
| Staging | 0.088 | ||
| I/II | 13(32.5) | 21(51.2) | |
| III/IV | 27(67.5) | 20(48.8) | |
| B symptom | 0.43 | ||
| Positive | 15(37.5) | 12(29.3) | |
| Negative | 25(62.5) | 29(70.7) | |
| PS | 0.41 | ||
| 0,1 | 38(95) | 37(90.2) | |
| 2,3,4 | 2(5) | 4(9.8) | |
| LDH | 0.75 | ||
| ≤ Normal value | 22(55) | 24(58.5) | |
| > Normal value | 18(45) | 17(41.5) | |
| Extranodal sites | 0.42 | ||
| 0–1 | 34(85) | 32(78) | |
| > 1 | 6(15) | 9(22) | |
| Liver involvement | 0.63 | ||
| Yes | 7(17.5) | 5(12.2) | |
| No | 33(82.5) | 36(87.8) | |
| Spleen involvement | 0.50 | ||
| Yes | 12(30) | 11(26.8) | |
| No | 28(70) | 30(73.2) | |
| HBV status prior to CT | 0.38 | ||
| HBsAg(+), HBeAg(+), Anti-HBc(+) | 11(27.5) | 15(36.6) | |
| HBsAg(+), Anti-HBe(+), Anti-HBc(+) | 29(72.5) | 26(63.4) | |
| Liver dysfunction prior to CT | 0.38 | ||
| Yes | 10(25) | 7(17.1) | |
| No | 30(75) | 34(82.9) | |
| Radiation | 0.037 | ||
| Yes | 8(20) | 17(41.5) | |
| No | 32(80) | 24(58.5) | |
| Chemotherapy | 0.90 | ||
| No. Range | 2–20 | 1–13 | |
| Median | 6 | 6 | |
| Response to front-line chemotherapy | 0.26 | ||
| CR | 18(45) | 25(61) | |
| PR | 19(47.5) | 12(29.3) | |
| SD | 1(2.5) | 3(7.3) | |
| PD | 2(5) | 1(2.4) |